David Roman
Stock Analyst at Goldman Sachs
Total Price Targets
38
Stocks Covered
22
Sectors
Healthcare
Most Recent
Apr 10, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by David Roman
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| BDX | Becton, Dickinson and Company | $167.00 | $149.07 | +12.0% | 2 | Apr 10, 2026 |
| TNDM | Tandem Diabetes Care, Inc. | $28.00 | $19.34 | +44.8% | 3 | Feb 23, 2026 |
| PODD | Insulet Corporation | $326.00 | $175.12 | +86.2% | 2 | Feb 19, 2026 |
| EW | Edwards Lifesciences Corporation | $95.00 | $84.24 | +12.8% | 4 | Feb 11, 2026 |
| OMDA | Omada Health | $26.00 | $15.30 | +69.9% | 1 | Jan 16, 2026 |
| BBNX | Beta Bionics, Inc. | $25.00 | $10.32 | +142.2% | 2 | Jan 15, 2026 |
| MDLN | Medline Inc. | $49.00 | $44.52 | +10.1% | 1 | Jan 12, 2026 |
| TDOC | Teladoc Health, Inc. | $9.00 | $6.48 | +38.9% | 1 | Jan 9, 2026 |
| BSX | Boston Scientific Corporation | $112.00 | $56.91 | +96.8% | 2 | Jan 9, 2026 |
| LIVN | LivaNova PLC | $66.00 | $61.04 | +8.1% | 2 | Jan 9, 2026 |
| ZBH | Zimmer Biomet Holdings, Inc. | $93.00 | $83.24 | +11.7% | 1 | Jan 9, 2026 |
| BLCO | Bausch + Lomb Corporation | $19.00 | $16.29 | +16.6% | 1 | Jan 9, 2026 |
| DOCS | Doximity, Inc. | $49.00 | $25.02 | +95.8% | 3 | Jan 9, 2026 |
| MDT | Medtronic plc | $111.00 | $80.42 | +38.0% | 2 | Nov 19, 2025 |
| BAX | Baxter International Inc. | $22.00 | $17.25 | +27.5% | 2 | Oct 31, 2025 |
| IRTC | iRhythm Technologies, Inc. | $202.00 | $119.47 | +69.1% | 2 | Oct 31, 2025 |
| COO | The Cooper Companies, Inc. | $64.00 | $62.51 | +2.4% | 1 | Oct 1, 2025 |
| ISRG | Intuitive Surgical, Inc. | $604.00 | $459.71 | +31.4% | 2 | Oct 18, 2024 |
| SYK | Stryker Corporation | $372.00 | $297.71 | +25.0% | 1 | May 30, 2024 |
| SOLV | Solventum Corporation | $54.00 | $66.97 | -19.4% | 1 | May 30, 2024 |
| ABT | Abbott Laboratories | $121.00 | $89.76 | +34.8% | 1 | May 30, 2024 |
| GEHC | GE HealthCare Technologies Inc. | $87.00 | $61.13 | +42.3% | 1 | May 30, 2024 |
Recent Activity
- Apr 10, 2026— Set$167.00price target onBDX(Becton, Dickinson and Company)
- Feb 23, 2026— Set$28.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Feb 19, 2026— Set$326.00price target onPODD(Insulet Corporation)
- Feb 11, 2026— Set$95.00price target onEW(Edwards Lifesciences Corporation)
- Jan 16, 2026— Set$26.00price target onOMDA(Omada Health)
- Jan 15, 2026— Set$25.00price target onBBNX(Beta Bionics, Inc.)
- Jan 12, 2026— Set$49.00price target onMDLN(Medline Inc.)
- Jan 9, 2026— Set$66.00price target onLIVN(LivaNova PLC)
- Jan 9, 2026— Set$19.00price target onBLCO(Bausch + Lomb Corporation)
- Jan 9, 2026— Set$25.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Jan 9, 2026— Set$112.00price target onBSX(Boston Scientific Corporation)
- Jan 9, 2026— Set$49.00price target onDOCS(Doximity, Inc.)
- Jan 9, 2026— Set$9.00price target onTDOC(Teladoc Health, Inc.)
- Jan 9, 2026— Set$108.00price target onEW(Edwards Lifesciences Corporation)
- Jan 9, 2026— Set$365.00price target onPODD(Insulet Corporation)
- Jan 9, 2026— Set$93.00price target onZBH(Zimmer Biomet Holdings, Inc.)
- Nov 19, 2025— Set$111.00price target onMDT(Medtronic plc)
- Oct 31, 2025— Set$22.00price target onBAX(Baxter International Inc.)
- Oct 31, 2025— Set$202.00price target onIRTC(iRhythm Technologies, Inc.)
- Oct 29, 2025— Set$33.00price target onBBNX(Beta Bionics, Inc.)
Frequently Asked Questions
Who is David Roman?
David Roman is a stock analyst at Goldman Sachs covering 22 stocks primarily in Healthcare. They have issued 38 price targets since May 30, 2024.
What stocks does David Roman cover?
David Roman currently covers 22 stocks, including EW, TNDM, DOCS, BDX, PODD.
What is David Roman's latest price target?
David Roman's most recent price target was $167.00 on BDX (Becton, Dickinson and Company), set on Apr 10, 2026.
What is David Roman's highest price target?
David Roman's highest issued price target is $604.00 on ISRG, set on Oct 18, 2024.
More Analysts at Goldman Sachs
Coverage based on publicly published price targets. Not investment advice.